Cefodizime is a new cephalosporin antibiotic with a wide range of biological activities.Cefodizime is non-toxic to the kidneys and is well tolerated with immunomodulatory activity.Cefodizime has antimicrobial activity and is used in the study of serious infections of the respiratory and urinary systems.

Cefodizime displays modest yet variable inhibitory effects against Citrobacter species, including Citrobacter freundii, and Serratia marcescens. It also inhibits other Gram-negative bacteria, such as Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Neisseria meningitidis. Cefodizime is a bactericidal antibiotic with a strong affinity for penicillin-binding proteins 1A/B, 2, and 3 in E. coli. In vitro, the concentrations of Cefodizime required for bactericidal activity against susceptible strains of both Gram-positive and Gram-negative bacteria are generally comparable to the minimum inhibitory concentrations.[1]

Cefodizime (50 mg/kg; S.C.; single; experimentally-induced K. pneumoniae respiratory tract infections in mice) exhibits activity comparable to Cefotaxime and Ceftazidime and surpassing that of Cefoperazone, Latamoxef, Cefuroxime, or cefazolin for the initial 8 hours. In contrast to these cephalosporins, Cefodizime maintains significant bactericidal activity for a duration of at least 48 hours after a single injection. Although Cefodizime can no longer be detected in the serum, it achieves complete bacterial clearance from the lungs within 48 hours in 50% of the mice.[1]